Table IV.
Genotype distribution and ORs (95% CI) for associations between HOXB13 genotypes and prostate cancer risk stratified by Gleason score and stage
| Genotype | Cases (n=1,310) | Controls (n=1,259) | ORa,b,c | 95% CI | ||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Gleason score ≤ 7d (n=750) | ||||||
| GG | 742 | (98.9) | 1,254 | (99.6) | 1.00 | (reference) |
| GA | 8 | (1.1) | 5 | (0.4) | 2.71 | (0.88–8.30) |
| Gleason score ≥ 7e (n=556) | ||||||
| GG | 547 | (98.4) | 1,254 | (99.6) | 1.00 | (reference) |
| GA | 9 | (1.6) | 5 | (0.4) | 4.13 | (1.38–12.38) |
| Local stage (n=1,020) | ||||||
| GG | 1,008 | (98.8) | 1,254 | (99.6) | 1.00 | (reference) |
| GA | 12 | (1.2) | 5 | (0.4) | 2.98 | (1.04–8.49) |
| Regional/distant stage (n=290) | ||||||
| GG | 285 | (98.3) | 1,254 | (99.6) | 1.00 | (reference) |
| GA | 5 | (1.7) | 5 | (0.4) | 4.47 | (1.28–15.57) |
a
Adjusted for age.
b
Heterogeneity by Gleason score: p=0.39.
c
Heterogeneity by stage: p=0.45.
d
Includes Gleason 3+4.
e
Includes Gleason 4+3.